Products
Online Inquiry
BRD7389
Cat. No.:
0225LY-0554
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BRD7389 targets the RSK kinase family as an inhibitor, yielding IC50 values of 1.5 μM for RSK1, 2.4 μM for RSK2, and 1.2 μM for RSK3.
Synonym:
376382-11-5; 1-(Phenethylamino)-3H-naphtho[1,2,3-de]quinoline-2,7-dione; 1-Phenethylamino-3H-naphtho[1,2,3-de]quinoline-2,7-dione; 1-[(2-Phenylethyl)amino]-H-naphtho[1,2,3-de]quinoline-2,7-dione
CAS No.:
376382-11-5
Compound CID:
1080352
Formula:
C24H18N2O2
Formula Weight:
366.41
Specification
Targets&IC50:
RSK1: 1.5 μM; RSK2: 2.4 μM; SGK: 13.8 μM; RSK3: 1.2 μM; FLT3: 3.5 μM; CDK5-p35: 6.5 μM; PKG1α: 6.5 μM; DRAK1: 2.8 μM; Pim1: 3.7 μM
Relative Density:
1.35 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BRD7389 can be used in diabetes research to explore the induction of insulin expression in pancreatic alpha cells.
Library Information
Target:
DAPK; SGK; Pim; FLT; CDK; S6 Kinase
Receptor:
RSK1; RSK2; RSK3; CDK5/p35; DRAK1; FLT3; Pim1; SGK
Pathways:
Angiogenesis; Tyrosine kinase/adaptors; Apoptosis; Cell cycle/Checkpoint; JAK/STAT signaling; MAPK; Chromatin/Epigenetic; Metabolism; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-8
Plate Location:
b8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
20 mg/mL; 54.58 mM
